Chicago Capital LLC Has $637,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Chicago Capital LLC lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 10.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 11,262 shares of the biopharmaceutical company’s stock after selling 1,275 shares during the period. Chicago Capital LLC’s holdings in Bristol-Myers Squibb were worth $637,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Algert Global LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $328,000. AMF Tjanstepension AB increased its stake in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after purchasing an additional 39,419 shares in the last quarter. Czech National Bank increased its stake in Bristol-Myers Squibb by 6.9% in the third quarter. Czech National Bank now owns 413,002 shares of the biopharmaceutical company’s stock valued at $21,369,000 after purchasing an additional 26,718 shares in the last quarter. GAMMA Investing LLC raised its holdings in Bristol-Myers Squibb by 61.3% in the third quarter. GAMMA Investing LLC now owns 27,386 shares of the biopharmaceutical company’s stock worth $1,417,000 after purchasing an additional 10,410 shares during the period. Finally, Everpar Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 4.1% during the third quarter. Everpar Advisors LLC now owns 11,242 shares of the biopharmaceutical company’s stock worth $582,000 after purchasing an additional 446 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Wolfe Research started coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets lifted their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Finally, Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $56.60.

Bristol-Myers Squibb Trading Up 1.8 %

NYSE BMY opened at $60.03 on Tuesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The stock has a 50 day moving average of $57.60 and a 200-day moving average of $53.34. The company has a market cap of $121.76 billion, a PE ratio of -16.72, a PEG ratio of 2.10 and a beta of 0.45.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.13%. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.